 |
Prospector
Profile
07.1080
|
| |
| ALCiS Health, Inc. |
NAICS |
325412 |
| 2001 Gateway Place, Suite 520W
San Jose, CA 95110 |
Description |
Pharmaceuticals Mfg. |
| (408) 437-1060 |
Employees |
11 |
| http://www.alcis.com/ |
Revenue |
(mil) |
2.2780 |
| |
Income |
(mil) |
-5.4110 |
| |
Assets |
(mil) |
2.2240 |
| |
Liability |
(mil) |
0.6370 |
| |
(for the year ended 2007-03-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
ALCiS Health, Inc. reported a net loss of $5,411,162 on revenues of $2,278,134 for the year ended March 31, 2007, compared to a net loss of $3,317,791 on revenues of $757,219 reported during the previous fiscal year. It also has an accumulated deficit of $10,120,870 as of March 31, 2007.
|
| |
|
Intellectual Property:
ALCiS has exclusively licensed certain technology from BioZone Laboratories, Inc. for its primary target market of topical analgesic pain relief products, known as “LDS” (liposome delivery system). Certain aspects of the proprietary technology are covered by recently awarded U.S. patents. The Company has also obtained an option from BioZone to purchase certain broader rights related to this technology. The Company has currently has registered U.S. trademarks for “THE SCIENCE OF RELIEF,” “ALCIS” and “ENGINEERED THERAPY FOR MUSCLES AND JOINTS.” [SEC Filing 10-KSB 07-13-07]
|
| |
|
Description:
The Company is engaged in the research, development, marketing and distribution of body therapy solutions, including pain management products such as topical analgesics.
|
| |
|
Officers:
Douglas Glader (Chair); Brian J. Berchtold (Pres., CEO & Dir.); Mark E. Lemma (CFO); David Booth (Dir.); Jerry Jarrell Allen F. Campbell Ravinder Sajwan David Scoffone
|
| |
|
Auditor:
Pannell Kerr Forster of Texas PC
|
| |
|
Securities:
8,961,902 common shares outstanding as of June 15, 2007.
|
| |
| |
| |
| return to main page |
|
|
